Antigua and Barbuda vs Qatar: Prevalence rate of hypertension in men aged 30-79
Antigua and Barbuda
41.9
in 2019
Qatar
41.6
in 2019
Antigua and Barbuda rank
56th
Qatar rank
59th
Prevalence rate of hypertension in men aged 30-79 over time
- Antigua and Barbuda
- Qatar
How they compare
Antigua and Barbuda currently reports 41.9 against 41.6 in Qatar, a difference of 0.3.
The two have swapped places 1 time across 30 shared years of data; in 1990 it was Qatar ahead.
Antigua and Barbuda ranks 56th and Qatar ranks 59th of 195 countries.
Qatar has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Antigua and Barbuda | Qatar | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 37.74 | 42.08 | 4.34 | Qatar |
| 2000s | 40.36 | 43.48 | 3.12 | Qatar |
| 2010s | 41.78 | 42.33 | 0.55 | Qatar |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence rate of hypertension in men aged 30-79, Antigua and Barbuda or Qatar?
- Antigua and Barbuda, at 41.9 against 41.6 in Qatar as of 2019.
- What is the difference in prevalence rate of hypertension in men aged 30-79 between Antigua and Barbuda and Qatar?
- 0.3, with Antigua and Barbuda ahead.
- How many years of comparable data are there for Antigua and Barbuda and Qatar?
- 30 years are reported by both, from 1990 to 2019.
- How do Antigua and Barbuda and Qatar rank globally for prevalence rate of hypertension in men aged 30-79?
- Antigua and Barbuda ranks 56th and Qatar ranks 59th of 195 countries.
- Where does this data come from?
- World Health Organization - Global Health Observatory (2026) – with minor processing by Our World in Data, published as Prevalence rate of hypertension in men aged 30-79. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Estimated share of male population with hypertension, based on population representative surveys and statistical modeling. Hypertension is a risk factor for chronic complications, including cardiovascular disease, and premature death.